|
| Status |
Public on Nov 04, 2022 |
| Title |
Patient_42, Serum, RA |
| Sample type |
protein |
| |
|
| Source name |
Serum
|
| Organism |
Homo sapiens |
| Characteristics |
patient label: Patient_42
disease state: RA
batch: JRD-17
Sex: F
age: 57
siltuximab_trial_participant: NA
study_arm: NA
cycle_derived: NA
siltuximab_response: NA
|
| Extracted molecule |
protein |
| Extraction protocol |
Protein extracted from serum in accordance with SomaLogic standard operating procedures and best practices.
|
| Label |
n.a.
|
| Label protocol |
Label protocol done in accordance with SomaLogic standard operating procedures and best practices.
|
| |
|
| Hybridization protocol |
Hybridization protocol done in accordance with SomaLogic standard operating procedures and best practices.
|
| Scan protocol |
Scan protocol done in accordance with SomaLogic standard operating procedures and best practices.
|
| Description |
JRD17.xlsx
2.5 PX-17-116.HybMedNormCal.Premium.adat
|
| Data processing |
SomaLogic SOMAscan pre-processing was performed, and 1,178 analytes passed quality control. Data were log2 transformed and capped at 2.5th and 97.5th percentiles. Batches were bridged together by the average log ratio of technical replicates for each analyte. Following quality control sample exclusion, pretreatment samples available for analysis included 88 iMCD patients, 42 healthy donors, and 20 each of RA, HL, and HHV8-MCD. Longitudinal samples available for analysis included samples from day 8 and day 64 of treatment from 73 iMCD patients.
|
| |
|
| Submission date |
Nov 04, 2022 |
| Last update date |
Nov 04, 2022 |
| Contact name |
David Fajgenbaum |
| E-mail(s) |
Davidfa@pennmedicine.upenn.edu
|
| Organization name |
University of Pennsylvania
|
| Department |
Medicine
|
| Lab |
Center for Cytokine Storm Treatment & Laboratory (CSTL)
|
| Street address |
3535 Market St, 717
|
| City |
Philadelphia |
| State/province |
PA |
| ZIP/Postal code |
19104 |
| Country |
USA |
| |
|
| Platform ID |
GPL23119 |
| Series (1) |
| GSE217351 |
CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease |
|
